Cialis and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

How Each Drug Is Cleared by the Body

Understanding why the tadalafil-rosuvastatin combination is generally safe starts with the pharmacokinetics of each agent. The two drugs travel through largely separate metabolic corridors, which limits the opportunity for a meaningful drug-drug interaction (DDI).

Tadalafil Pharmacokinetics

Tadalafil is absorbed orally with a bioavailability of approximately 15 to 50% and reaches peak plasma concentration (Tmax) at roughly 2 hours [1]. It is metabolized almost exclusively by hepatic CYP3A4 into an inactive catechol glucuronide metabolite [1]. Tadalafil is not a substrate of the organic-anion transporting polypeptides OATP1B1 or OATP1B3, the hepatic uptake transporters most relevant to statin disposition [2]. Its half-life of approximately 17.5 hours is the pharmacological basis for once-daily dosing at 5 mg [1].

Renal impairment (CrCl <30 mL/min) reduces tadalafil clearance meaningfully, requiring dose reduction or avoidance. Hepatic impairment (Child-Pugh Class B) limits the maximum dose to 10 mg [1].

Rosuvastatin Pharmacokinetics

Rosuvastatin behaves quite differently. It undergoes minimal CYP2C9-mediated metabolism (approximately 10%) and is therefore not vulnerable to CYP3A4 inhibitors the way simvastatin and atorvastatin are [3]. Its plasma-exposure profile is driven primarily by hepatic uptake via OATP1B1 and OATP1B3 transporters and efflux via BCRP (breast cancer resistance protein) [3].

Drugs that inhibit OATP1B1/1B3, cyclosporine, gemfibrozil, elbasvir/grazoprevir, can raise rosuvastatin AUC by 2- to 10-fold, dramatically increasing myopathy risk [4]. The FDA label for rosuvastatin mandates a 10 mg/day dose ceiling when co-administered with cyclosporine [4]. Tadalafil does not meaningfully inhibit OATP1B1 or OATP1B3 in vitro or at clinically relevant plasma concentrations [2].

The Core Pharmacokinetic Question: Does Tadalafil Raise Rosuvastatin Exposure?

No published pharmacokinetic study has demonstrated a clinically significant increase in rosuvastatin AUC or Cmax attributable to tadalafil co-administration [5]. The FDA prescribing information for tadalafil lists no required dose adjustment for statins as a drug class [1]. The rosuvastatin FDA label identifies specific OATP inhibitors by name, cyclosporine, gemfibrozil, lopinavir/ritonavir, and tadalafil does not appear on that list [4].

Why OATP Transport Is the Deciding Factor

Because rosuvastatin's systemic exposure depends so heavily on OATP1B1/1B3 function, any clinically important interaction must involve these transporters. Tadalafil's IC50 values against OATP1B1 and OATP1B3 in transporter assays exceed the free drug concentrations achieved in portal blood at therapeutic doses [2]. The free plasma Cmax of tadalafil 20 mg is approximately 378 ng/mL (roughly 0.9 micromolar), well below the concentrations needed to produce 50% OATP1B1 inhibition in cellular assays [1,2].

This means the hepatic uptake of rosuvastatin proceeds essentially unimpeded when tadalafil is present, and rosuvastatin's therapeutic cholesterol-lowering effect is preserved.

CYP Pathway Cross-Talk

Tadalafil is metabolized by CYP3A4 but does not meaningfully inhibit or induce CYP3A4 at therapeutic concentrations [1]. Because rosuvastatin is not a CYP3A4 substrate, this pathway is irrelevant to the interaction regardless. There is no CYP-mediated competition between these two agents [3].

Muscle Safety: Could Tadalafil Worsen Statin Myopathy Risk?

Statin-associated muscle symptoms (SAMS) affect 5 to 10% of statin users in real-world practice, though randomized controlled trial data report lower rates [6]. Rosuvastatin carries a class-wide myopathy risk, and any co-medication that raises rosuvastatin plasma exposure increases that risk proportionally.

Evidence Basis for Muscle Risk Assessment

No randomized trial or prospective pharmacovigilance study has identified tadalafil as a potentiator of rosuvastatin-associated myopathy [5]. The MedWatch FDA adverse event reporting system and the WHO VigiBase have not generated a disproportionality signal linking this specific combination to rhabdomyolysis or severe myopathy at the time of this review. Published statin interaction literature consistently identifies the highest-risk combinations as those involving OATP1B1 inhibitors (cyclosporine: 7-fold AUC increase), BCRP inhibitors (fostamatinib), or CYP2C9 inhibitors (fluconazole: approximately 2-fold AUC increase), not PDE5 inhibitors [4,7].

When to Check Creatine Kinase

The American College of Cardiology / American Heart Association 2022 statin guidance does not recommend routine baseline creatine kinase (CK) measurement in all statin users [8]. Checking CK is appropriate if a patient reports muscle pain, weakness, or dark urine. Adding tadalafil to a stable rosuvastatin regimen does not independently lower the threshold for CK testing. If a patient is already experiencing SAMS and adds tadalafil, the workup should follow standard statin myopathy protocols, evaluate rosuvastatin dose, assess for hypothyroidism, and review all co-medications that genuinely affect rosuvastatin exposure [8].

Cardiovascular Pharmacodynamics: Shared Territory in Men With ED and Dyslipidemia

Men prescribed both tadalafil and rosuvastatin often share a cardiometabolic phenotype: they are middle-aged or older, carry a diagnosis of erectile dysfunction and dyslipidemia, and may have hypertension or early coronary artery disease. Erectile dysfunction itself is an independent cardiovascular risk marker, the Massachusetts Male Aging Study and subsequent meta-analyses confirm that ED precedes a cardiovascular event by 2 to 5 years in a meaningful proportion of affected men [9].

Pharmacodynamic Interactions to Monitor

Tadalafil produces vasodilation by inhibiting phosphodiesterase type 5, raising cyclic GMP in vascular smooth muscle [1]. This mechanism creates one clinically serious pharmacodynamic interaction, co-administration with any nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) is absolutely contraindicated due to the risk of severe, potentially fatal hypotension [1]. Rosuvastatin does not potentiate this effect and does not alter tadalafil's hemodynamic profile.

Rosuvastatin itself has modest blood-pressure-neutral effects and does not cause hypotension [4]. Patients taking both drugs alongside antihypertensives should monitor blood pressure at routine intervals per their treating physician's guidance, but this monitoring is driven by tadalafil's mild vasodilatory effect, not by any additive interaction with rosuvastatin.

Erectile Dysfunction as a Window Into Cardiovascular Risk

The Princeton III Consensus guidelines on sexual activity and cardiac risk recommend stratifying patients with ED into low, intermediate, and high cardiovascular risk before initiating PDE5 inhibitor therapy [10]. A patient stable on rosuvastatin for primary or secondary cardiovascular prevention is often already in the low-risk category for sexual activity. The two medications can coexist as part of a coherent cardiometabolic management plan.

The following framework reflects the HealthRX clinical decision logic for evaluating tadalafil co-medications in men receiving statin therapy. It is intended for use by prescribing clinicians during medication reconciliation:

HealthRX Tadalafil-Statin DDI Decision Framework (v1.0)

| Statin | Primary Clearance | CYP3A4 Sensitive? | OATP Sensitive? | Tadalafil DDI Risk | Action | |---|---|---|---|---|---| | Rosuvastatin | OATP1B1/1B3, BCRP | No | Yes | Minimal | No dose change needed | | Atorvastatin | CYP3A4, OATP | Yes | Yes | Low-moderate | Monitor at high atorvastatin doses | | Simvastatin | CYP3A4 | Yes | Partial | Low-moderate | Prefer lower simvastatin doses | | Pravastatin | Renal, OATP | No | Yes | Minimal | No dose change needed | | Fluvastatin | CYP2C9 | No | No | Minimal | No dose change needed |

Note: "Moderate" CYP3A4 inhibitors that co-prescribers sometimes confuse with tadalafil include ketoconazole and itraconazole; those agents require tadalafil dose limits and may affect atorvastatin/simvastatin exposure. Tadalafil itself is not a CYP3A4 inhibitor.

What the FDA Labels Actually Say

Both the tadalafil (Cialis) FDA prescribing information and the rosuvastatin (Crestor) FDA label are publicly searchable on the FDA's Access Data portal.

Tadalafil FDA Label: Drug Interaction Section

The tadalafil label identifies the following clinically significant interactions (abridged) [1]:

• Strong CYP3A4 inhibitors (ketoconazole, ritonavir): increase tadalafil AUC significantly; reduce tadalafil dose to 10 mg no more than once every 72 hours with ritonavir.
• Strong CYP3A4 inducers (rifampin): reduce tadalafil AUC by approximately 88%; avoid concurrent use or expect substantially reduced efficacy.
• Nitrates: absolute pharmacodynamic contraindication.
• Alpha-blockers: moderate additive hypotension; titrate carefully.
• Antihypertensives: mild additive blood-pressure lowering; counsel patients.

Statins, including rosuvastatin, are not listed as drugs requiring any tadalafil dose modification [1].

Rosuvastatin FDA Label: Drug Interaction Section

The rosuvastatin label specifies these interactions requiring dose adjustment [4]:

• Cyclosporine: maximum 5 mg/day rosuvastatin.
• Gemfibrozil: avoid combination (2.0-fold AUC increase plus pharmacodynamic muscle risk).
• Lopinavir/ritonavir or atazanavir/ritonavir: maximum 10 mg/day.
• Elbasvir/grazoprevir: maximum 10 mg/day.
• Fostamatinib: maximum 20 mg/day.

PDE5 inhibitors including tadalafil are absent from the rosuvastatin interaction table entirely [4].

Clinical Scenarios and Practical Guidance

Scenario 1: New Tadalafil Prescription in a Man Already on Rosuvastatin

A 54-year-old man presents with ED and is currently taking rosuvastatin 20 mg nightly, amlodipine 5 mg, and low-dose aspirin. He is otherwise healthy with an LDL of 88 mg/dL on statin therapy. His physician considers tadalafil 5 mg once daily.

No pharmacokinetic interaction requires dose modification of either drug [1,4]. The prescriber should confirm the absence of nitrate use (absolute contraindication), review blood pressure response to amlodipine since tadalafil may produce a modest additional antihypertensive effect, and document the cardiovascular risk assessment per Princeton III principles [10]. Rosuvastatin dose remains at 20 mg. Tadalafil starts at 5 mg once daily per standard initiation practice.

Scenario 2: Rosuvastatin Added to Established Tadalafil Therapy

A 61-year-old man with BPH on tadalafil 5 mg once daily is newly diagnosed with hyperlipidemia. His cardiologist initiates rosuvastatin 10 mg nightly.

Again, no dose modification is required due to the interaction between these two specific agents [1,4]. The prescriber should use standard shared decision-making for statin initiation per the ACC/AHA 2019 cholesterol guidelines, which recommend a pooled cohort equations risk calculation and discussion of statin benefit in the context of the patient's 10-year ASCVD risk [8]. Tadalafil continues unchanged.

Scenario 3: High-Dose Rosuvastatin and Maximum Tadalafil

A 67-year-old man with a prior myocardial infarction is taking rosuvastatin 40 mg (high-intensity statin per ACC/AHA guidelines) and uses tadalafil 20 mg as needed for ED. He asks his cardiologist whether these doses are safe together.

The pharmacokinetic data support this combination without mandatory dose changes between these two agents specifically [1,4,5]. His risk for rosuvastatin-associated myopathy at 40 mg is slightly higher than at lower doses as a class effect, but tadalafil does not magnify that baseline risk. Standard monitoring applies: ask about muscle symptoms at each visit, check CK if he reports myalgia, and confirm he is not using any nitrate for his ischemic heart disease (an absolute contraindication with tadalafil) [1,8].

Counseling Points for Patients

Short, clear counseling saves appointments. Patients asking about this combination deserve direct answers, not vague reassurance.

What to Tell Patients Who Ask Directly

"Your Crestor and your Cialis use different pathways in the liver and do not significantly interfere with each other. Your cholesterol medication will still work, and your Cialis dose does not need to change because of your statin."

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction notes that "medication reconciliation for patients on statin therapy should focus on OATP1B1/1B3 inhibitors, CYP2C9 inhibitors, and fibrates as the highest-yield targets for interaction review" [8]. Tadalafil falls outside all three categories.

What Patients Must Still Avoid With Tadalafil

• Any nitrate in any form: nitroglycerin tablets, patches, sprays, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite ("poppers"). This contraindication is absolute and fatal hypotension has occurred [1].
• Recreational phosphodiesterase-pathway drugs combined with antihypertensives: instruct patients to sit or stand slowly to avoid orthostatic hypotension, especially in the first 1 to 2 hours after dosing.
• Grapefruit juice in large amounts: it inhibits intestinal CYP3A4 and can raise tadalafil exposure, though moderate amounts (one glass) carry low clinical significance [1].

Drug Interaction Databases: How They Rate This Combination

Major clinical decision-support tools (Lexicomp, Micromedex, Clinical Pharmacology) currently classify the tadalafil-rosuvastatin interaction as "no known interaction" or "minor." These ratings align with the mechanistic data: the two drugs do not share a CYP pathway in a clinically significant way, tadalafil is not an OATP1B1/1B3 inhibitor at therapeutic concentrations, and no published outcome data support clinical harm from the combination [5,11].

The FDA's drug interaction guidance for industry specifies that an inhibitor's clinical relevance depends on achieving a ratio of its unbound plasma Cmax to the transporter's in vitro IC50 that is greater than 0.1 for OATP1B1 [11]. Tadalafil does not meet this threshold for OATP1B1 inhibition, which is why the FDA label carries no rosuvastatin-specific warning [1,11].

Summary of Monitoring Recommendations

Patients on the tadalafil-rosuvastatin combination should follow standard monitoring for each agent independently. No additional tests are required specifically because of the co-administration.

Rosuvastatin Monitoring (Standard)

• Fasting lipid panel 4 to 12 weeks after initiation or dose change, then annually [8].
• Liver enzymes only if symptoms of hepatotoxicity arise; routine liver function testing is not recommended by current ACC/AHA guidelines [8].
• CK measurement if the patient reports muscle pain, weakness, or brown urine [8].
• HbA1c at baseline and annually in patients at diabetes risk, since statins modestly increase diabetes incidence at high intensity (rosuvastatin 20 to 40 mg) [12].

Tadalafil Monitoring (Standard)

• Blood pressure check at initiation and after dose changes, particularly in patients on antihypertensives [1].
• Screen for nitrate use at every prescription renewal [1].
• Assess for vision changes (non-arteritic anterior ischemic optic neuropathy is a rare reported association) [1].
• PSA monitoring per urology guidance if tadalafil is used for BPH [13].